Biogen Inc 's Cash & cash equivalent grew by 10.31 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Biogen Inc 's Quick Ratio to 0.16, Quick Ratio remained below Biogen Inc average.

Within Biotechnology & Pharmaceuticals industry 135 other companies have achieved higher Quick Ratio than Biogen Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 3126, from total ranking in the second quarter 2026 at 4070.

Explain Quick Ratio?
How much Cash & cash equivalents BIIB�s has?
What are BIIB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BIIB/financial-strength

https://api.csimarket.com/api/v1/companies/BIIB/fundamentals

https://api.csimarket.com/api/v1/companies/BIIB/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

BIIB Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	18.49 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	543.55 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.16	Subscribe	Subscribe	Subscribe	Subscribe
BIIB's Total Ranking	# 3126	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-0.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	10.31 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 136
Healthcare Sector	# 835
Overall Market	# 3537

Quick Ratio Statistics
High	Average	Low
3.22	1.08	0.03
(Dec. 31, 2005)		(Sep 30 2025)

Financial Statements
Biogen Inc 's Current Liabilities	$ 3,898 Millions	Visit BIIB's Balance sheet
Biogen Inc 's Cash & cash equivalent	$ 628 Millions	Visit BIIB's Balance sheet
Source of BIIB's Sales		Visit BIIB's Sales by Geography

Cumulative Biogen Inc 's Quick Ratio

BIIB's Quick Ratio for the trailling 12 Months

BIIB Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-18.13 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	2876.13 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.21	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3233	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	4.49 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	22.34 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to BIIB Financial Strength Comparisons >> Go to Compare BIIB Quick Ratio to its Competitors

On the trailing twelve months basis BIIB Cash & cash equivalent more than doubled by 543.55 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Biogen Inc 's Quick Ratio to 0.21, Quick Ratio remained below BIIB average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 136 other companies have achieved higher Quick Ratio than Biogen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 953 to 3233.

Explain Quick Ratio?
How much Cash & cash equivalents BIIB�s has?
What are BIIB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 137
Healthcare Sector	# 848
Within the Market	# 3233

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.87	0.99	0.01
(Dec. 31, 2009)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Agenus Inc	0.43	$ 86.936 Millions	$ 203.691 Millions
Vaxcyte Inc	0.42	$ 125.470 Millions	$ 295.697 Millions
Vaxart Inc	0.41	$ 30.435 Millions	$ 73.934 Millions
Surrozen Inc	0.35	$ 100.353 Millions	$ 286.684 Millions
Biogen Inc	0.16	$ 628.100 Millions	$ 3,898.400 Millions
Viskase Holdings inc	0.04	$ 7.747 Millions	$ 210.729 Millions

Date modified: 2026-10-29T17:22:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.